Crossmark

Adis summary of research: Efficacy and safety of esketamine nasal spray in patients with treatment-resistant depression who completed a second induction period: analysis of the ongoing SUSTAIN-3 study

Crossref DOI link: https://doi.org/10.1007/s40267-024-01106-4

Published Online: 2024-10-16

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hoy, Sheridan M.
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Accepted: 26 August 2024

First Online: 16 October 2024

Declarations

:

: The preparation of this review was not supported by any external funding.

: Sheridan M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

: Not applicable.

Document is current

Any future updates will be listed below